The design bet behind a GLP-1/glucagon dual agonist is that GLP-1s insulinotropic, appetite-suppressing, glucose-lowering effects can be used to offset the hyperglycemic tendency of glucagon, while glucagons thermogenic and hepatic-lipid effects add weight-loss and liver-directed benefits that GLP-1 alone does not deliver
I'm just glad you're here.
The decision, buried within the Department of Health Care Services (DHCS) cost-saving adjustments, comes after a year in which these drugs accounted for more than $1.6 billion in Medicaid reimbursements statewide
In fact, her study found that people who were overweight according to their body mass index (BMI) (meaning a BMI between 25 and 30) had no increased risk of death compared with people whose BMIs fell in the normal range (18.5 to 25)
Andrologia 54(9):e14508
FOR IMMEDIATE RELEASE FROM MARY ANN LIEBERT, INC., PUBLISHERS New Rochelle, NY, January 8, 2025 A new study found no evidence that glucagon-like peptide 1 receptor agonist (GLP1-RA) use is associated with an increased risk of thyroid cancer
